Healthcare Providers Adjust to Anti-Information Blocking Regulation Impact on Patient Interactions
Premium
The regulations have received a tepid reception from some doctors worried about patients finding out sensitive information online without support.
Researchers Look to Validate Promising Immunotherapy Response Biomarker in Early-Stage Breast Cancer
Premium
MHC-II expression could be useful for guiding neoadjuvant immunotherapy in HER2-negative breast cancers, according to findings in Clinical Cancer Research.
The drug, MS21, has shown preclinically to inhibit growth of tumor cells with mutations in the PI3K/PTEN/AKT pathway.
Gilead Sciences Q2 Revenues Grow 21 Percent as CAR T-Cell Business Jumps 39 Percent
Revenues from pharmaceutical products were almost entirely driven by the COVID-19 treatment remdesivir, though sales of Kite Pharma's CAR T-cell therapies grew, too.
Blueprint Medicines Q2 Revenues Increase More Than 200 Percent
In the second quarter, Blueprint reported $8.5 million in revenue from Ayvakit and $2.9 million in revenue from Gavreto.